Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AZASITE vs ALPRAZOLAM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.
Positive allosteric modulator of GABA-A receptors; enhances GABA inhibitory neurotransmission by binding to benzodiazepine site on GABA-A receptor, increasing chloride ion conductance.
Treatment of bacterial conjunctivitis caused by susceptible organisms
Generalized anxiety disorder,Panic disorder with or without agoraphobia,Anxiety (off-label),Insomnia (off-label),Chemotherapy-induced nausea and vomiting (off-label),Premenstrual dysphoric disorder (off-label)
1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.
0.25-0.5 mg orally 3 times daily; maximum 4 mg/day in divided doses.
Terminal elimination half-life: 68-72 hours; facilitates once-weekly dosing for trachoma.
12-15 hours (mean ~13 hours); prolonged in elderly (up to 19 hours) and hepatic impairment (up to 20-30 hours); clinical context: allows once- to twice-daily dosing, but risk of accumulation with high doses or in vulnerable populations
Not significantly metabolized; primarily excreted unchanged in bile and urine.
Primarily hepatic via CYP3A4; major metabolites are alpha-hydroxyalprazolam (active) and 4-hydroxyalprazolam (inactive).
Primarily hepatic/biliary (fecal) as unchanged drug: ~70% fecal, ~20% renal (mostly unchanged), ~0.5% urinary as metabolites.
Renal (approximately 80% as metabolites, <20% unchanged); fecal (minor, ~7%)
~50-60% bound to plasma proteins (primarily albumin).
80% (primarily to albumin, minor to α1-acid glycoprotein)
Vd: ~100 L/kg (extensive tissue penetration; not meaningful for topical use; systemic Vd based on IV data).
0.8 L/kg (range 0.6-1.2 L/kg); clinical meaning: moderate tissue distribution, reflects lipophilicity; higher Vd in obesity
Ophthalmic: negligible systemic absorption (<10% of topical dose) due to low corneal permeability and dilution by tears.
Oral: 90% (immediate-release); extended-release: approximately 90% relative to immediate-release; sublingual: approximately 75-80% of oral
No dosage adjustment required for ophthalmic use.
GFR 10-50 m L/min: reduce dose by 50%; GFR <10 m L/min: use with caution, reduce dose by 50% or consider alternative.
No dosage adjustment required for ophthalmic use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Safety and efficacy in pediatric patients have not been established; limited data available.
Not FDA-approved for <18 years; limited data: 0.125 mg/kg/dose orally 3 times daily (max 0.02 mg/kg/dose) for panic disorder in adolescents.
No specific dosage adjustment recommended; use same dosing as for adults.
Start with 0.25 mg orally 2-3 times daily; increase slowly due to increased sensitivity and risk of falls; maximum 2 mg/day.
None
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
Prolonged use may result in overgrowth of nonsusceptible organisms,Contact lens should not be worn during treatment,Do not inject subconjunctivally or introduce into the anterior chamber
Risk of abuse, misuse, and addiction; dependence and withdrawal reactions; respiratory depression; worsening of depression or suicidal ideation; use in patients with acute narrow-angle glaucoma; impaired motor and cognitive performance; risk of severe allergic reactions.
Hypersensitivity to azithromycin, erythromycin, or any macrolide antibiotic,Hypersensitivity to any component of the formulation
Concurrent use with ketoconazole or itraconazole; hypersensitivity to benzodiazepines; acute narrow-angle glaucoma; severe hepatic impairment; pregnancy (especially first trimester) and breastfeeding.
No clinically significant food interactions. Administer with or without food as per dosing instructions.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing alprazolam levels and risk of toxicity. Avoid alcohol. No other significant food interactions.
Azasite (azithromycin ophthalmic) is classified as FDA Pregnancy Category B. Systemic absorption is minimal after ophthalmic administration. No teratogenic effects have been observed in animal studies at doses up to 200 mg/kg/day (systemic). Limited human data; risk is considered low. First trimester: unlikely to cause major malformations. Second and third trimesters: no specific risks identified.
First trimester: Associated with increased risk of cleft lip/palate (OR 2.0); avoid if possible. Second/third trimester: Risk of benzodiazepine withdrawal or floppy infant syndrome (hypotonia, respiratory depression, feeding difficulties) with chronic high-dose use. Late third trimester: Risk of neonatal withdrawal syndrome.
Azithromycin is excreted into human milk after systemic administration; the M/P ratio is approximately 0.90. After ophthalmic administration, systemic absorption is minimal, resulting in negligible exposure to the infant. Considered compatible with breastfeeding; use with caution if eye drops are applied multiple times daily.
Excreted into breast milk; M/P ratio approximately 0.3-0.5. Relative infant dose ~2-3% of maternal weight-adjusted dose. Clinical significance: low but may cause sedation, poor feeding, or withdrawal in neonates. Use caution, monitor infant for lethargy and weight gain.
No dose adjustment is necessary for ophthalmic use in pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) do not significantly affect topical ocular drug levels due to negligible systemic absorption.
Increased clearance and volume of distribution in pregnancy may require dose up-titration. Monitor clinical response; consider increasing dose by 20-50% in second and third trimesters. Avoid abrupt discontinuation; taper if needed. Use lowest effective dose for shortest duration.
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic used for bacterial conjunctivitis. Shake well before each use. Avoid contact with contact lenses during treatment. Do not use for more than 14 days. Monitor for signs of hypersensitivity.
Alprazolam is a short-acting benzodiazepine with a rapid onset. Due to its high potency and short half-life, it carries a high risk of dependence and withdrawal. Avoid in patients with narrow-angle glaucoma, severe respiratory insufficiency, or myasthenia gravis. Use with caution in patients with history of substance abuse. Taper gradually to prevent rebound anxiety and seizures. Onset of action is 15-30 min orally; peak effect at 1-2 hours.
Shake the bottle well before each use.,Wash hands before and after application.,Do not touch the dropper tip to any surface.,Remove contact lenses before use; do not reinsert during treatment.,Instill the prescribed number of drops in the affected eye(s).,Avoid wearing eye makeup during treatment.,Finish the entire course of medication even if symptoms improve.,Report any worsening, itching, or swelling to your doctor.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other central nervous system depressants as they can cause severe sedation and respiratory depression.,Do not drive or operate heavy machinery until you know how alprazolam affects you; it may cause drowsiness or dizziness.,Do not stop abruptly; withdrawal symptoms can include anxiety, insomnia, seizures, and life-threatening reactions.,Store at room temperature away from moisture and heat. Keep out of reach of children.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Report any worsening of depression or suicidal thoughts immediately.
No interactions on record
"Alprazolam, a benzodiazepine, potentiates the central nervous system (CNS) depressant effects of tetracaine, an ester-type local anesthetic. This additive or synergistic interaction can lead to excessive sedation, respiratory depression, and hypotension, particularly in elderly or debilitated patients. Concurrent use may also increase the risk of seizures due to tetracaine's proconvulsant activity at high doses, which is compounded by alprazolam's withdrawal-associated seizure risk."
"Co-administration of alprazolam, a benzodiazepine, with indinavir, a potent CYP3A4 inhibitor, significantly increases alprazolam's serum concentration and half-life via reduced hepatic metabolism, leading to excessive sedation, respiratory depression, and impaired psychomotor function. Conversely, indinavir levels may be modestly increased due to competition for metabolism. This interaction poses a risk of severe central nervous system depression and should be avoided if possible."
"Concurrent use of alprazolam, a benzodiazepine with central nervous system depressant effects, and proparacaine, a topical ophthalmic anesthetic that can be systemically absorbed, may lead to additive CNS depression. This interaction can manifest as increased sedation, dizziness, confusion, or respiratory depression, especially in patients with compromised respiratory function or those receiving high doses of either agent. Clinicians should exercise caution when combining these drugs due to the potential for enhanced adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AZASITE vs ALPRAZOLAM, answered by our medical review team.
AZASITE is a Macrolide Antibiotic that works by Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.. ALPRAZOLAM is a Benzodiazepine that works by Positive allosteric modulator of GABA-A receptors; enhances GABA inhibitory neurotransmission by binding to benzodiazepine site on GABA-A receptor, increasing chloride ion conductance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AZASITE and ALPRAZOLAM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AZASITE is: 1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.. The standard adult dose of ALPRAZOLAM is: 0.25-0.5 mg orally 3 times daily; maximum 4 mg/day in divided doses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AZASITE and ALPRAZOLAM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AZASITE is classified as Category C. Azasite (azithromycin ophthalmic) is classified as FDA Pregnancy Category B. Systemic absorption is minimal after ophthalmic administration. No teratogenic effects have been observ. ALPRAZOLAM is classified as Category D/X. First trimester: Associated with increased risk of cleft lip/palate (OR 2.0); avoid if possible. Second/third trimester: Risk of benzodiazepine withdrawal or floppy infant syndrome. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.